SARS-CoV-2 Infection: Clinical Trials

161 completed, 72 unknown, 20 terminated, 11 withdrawn. 78 Phase 2, 55 Phase 3, 44 Not applicable, 38 Phase 1, 8 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	78	Completed 36, Unknown 21, Terminated 10, Withdrawn 6, Suspended 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 3	55	Completed 34, Unknown 9, Terminated 5, Withdrawn 4, Active not recruiting 1, Recruiting 1, Suspended 1
Not applicable	44	Completed 24, Unknown 12, Not yet recruiting 2, Recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 1	38	Completed 20, Unknown 9, Terminated 5, Recruiting 2, Active not recruiting 1, Not yet recruiting 1
Phase 4	8	Completed 4, Unknown 3, Active not recruiting 1
Early Phase 1	2	Completed 2

Follow SARS-CoV-2 Infection: new trials by email Literature Review of SARS-CoV-2 Infection trials Research Report on SARS-CoV-2 Infection

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test Flu A/B/COVID-19 + RSV Multiplex Rapid Test - SARS-CoV-2 Infection, Influenza A	Not applicable	Not yet recruiting	CorDx, Inc.	1500	2026-11-01	2026-10-15
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test CorDx Tyfast Flu A/B & COVID-19 At-Home Multiplex Rapid Test - SARS-CoV-2 Infection, Influenza A	Not applicable	Not yet recruiting	CorDx, Inc.	200	2026-02-12	2026-02-25
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age BNT162b2 Vaccine, Placebo - COVID-19, SARS-COV-2 Infection	Phase 3	Completed	BioNTech SE	5240	2025-12-10	2026-10-16
Cardiovascular Assessment 5 Years After MIS-C Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection		Recruiting	Medical University of Warsaw	90	2025-11-22	2026-06-22
Efficacy and Safety of NVX-CoV2705 NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection	Phase 4	Active not recruiting	Novavax	6500	2025-11-20	2026-05-08
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19 BNT162b2 (2025/2026 formulation) - COVID-19, SARS-COV-2 Infection	Phase 3	Completed	BioNTech SE	344	2025-10-30	2026-08-07
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo - COVID-19, SARS-CoV-2 Infection	Phase 1 / Phase 2	Recruiting	Kara Chew	80	2025-10-21	2026-08-18
Safety and Immunogenicity of NVX-CoV2705 NVX-CoV2705 - COVID-19, SARS-CoV-2 Infection	Phase 3	Completed	Sanofi	676	2025-10-09	2026-06-05
Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19) PepGNP-COVID19 (One vaccination), Water for injection (One vaccination), PepGNP-COVID19 (Two vaccinations) - Coronavirus, SARS-CoV-2 Infection	Phase 1 / Phase 2	Not yet recruiting	Gylden Pharma Ltd	110	2025-09-01	2025-02-24
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) - COVID-19, SARS-COV-2 Infection	Phase 3	Completed	BioNTech SE	774	2025-07-08	2026-06-01
Evaluation of the Diagnostic Performance of the TestNPass DM-DIV for SARS-CoV-2 Using a Nasopharyngeal Sample nasopharyngeal swab. - SARS-CoV-2 Infection	Not applicable	Completed	University Hospital, Grenoble	400	2025-04-30	2026-05-12
Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 eBAM Cov Testing - SARS-CoV-2 Infection, COVID-19	Not applicable	Recruiting	Centre Hospitalier Universitaire de Nīmes	250	2025-01-01	2026-05-27
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3 - SARS-CoV-2 Infection	Early Phase 1	Completed	Hvivo	36	2024-12-02	2025-11-21
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID Baricitinib, Placebo - Long COVID, Sars-CoV-2 Infection	Phase 3	Recruiting	Wes Ely	550	2024-10-21	2026-09-25
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. Remdesivir - SARS-CoV-2 Infection, COVID-19	Phase 4	Completed	University of Derby	73	2024-10-08	2026-02-20
COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study Omicron BA.5 SARS-CoV-2 challenge virus - SARS-CoV-2 Infection	Phase 1	Active not recruiting	University of Oxford	45	2024-08-08	2026-04-24
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV - Influenza, Human, SARS-CoV-2 Infection	Phase 2	Completed	Pfizer	644	2024-01-31	2025-09-30
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India Exposures - Influenza, COVID-19		Recruiting	Boston University	10000	2023-12-26	2025-11-28
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563 - COVID-19, SARS-CoV-2 Infection	Phase 1	Completed	AstraZeneca	243	2023-11-27	2026-08-31
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings Aptitude Medical Systems Metrix COVID/Flu Test - SARS-CoV-2 Infection, Influenza A	Not applicable	Completed	Aptitude Medical Systems	614	2023-11-20	2025-05-13

Showing 20 of 285. Sign in to see all of them.

Narrower conditions

COVID-19 (285)  ·  Coronavirus Infections (37)  ·  Post-Acute COVID-19 Syndrome (5)  ·  Severe Acute Respiratory Syndrome (5)  ·  Cognitive Dysfunction (4)  ·  Infections (4)  ·  Influenza, Human (4)  ·  Pneumonia (4)  ·  Pulmonary Fibrosis (4)  ·  Respiratory Distress Syndrome (4)  ·  Respiratory Tract Infections (4)  ·  Virus Diseases (4)  ·  Anosmia (3)  ·  Disease (3)  ·  Hematologic Neoplasms (3)

Broader conditions

Nidovirales Infections (285)  ·  Coronaviridae Infections (284)  ·  Lung Diseases (284)  ·  Respiratory Tract Diseases (284)  ·  Pneumonia, Viral (283)  ·  RNA Virus Infections (283)  ·  Infections (281)  ·  Pneumonia (281)  ·  Respiratory Tract Infections (281)  ·  Virus Diseases (281)  ·  Coronavirus Infections (248)  ·  Pathological Conditions, Signs and Symptoms (25)  ·  Pathologic Processes (19)  ·  Immune System Diseases (9)  ·  Signs and Symptoms (8)

Interventions

BNT162 Vaccine (24)  ·  SCTV01C vaccine (11)  ·  Blood Specimen Collection (8)  ·  COVID-19 Vaccines (7)  ·  Sodium Chloride (7)  ·  Standard of Care (5)  ·  sinovac COVID-19 vaccine (5)  ·  CVnCoV COVID-19 vaccine (4)  ·  ChAdOx1 nCoV-19 (4)  ·  Hydroxychloroquine (4)  ·  NVX-CoV2373 adjuvated lipid nanoparticle (4)  ·  2019-nCoV Vaccine mRNA-1273 (3)  ·  Azithromycin (3)  ·  Cetylpyridinium (3)  ·  TURKOVAC (3)

Sponsors

BioNTech SE (15)  ·  Sinocelltech Ltd. (12)  ·  Assistance Publique - Hôpitaux de Paris (5)  ·  Novavax (5)  ·  Pfizer (5)  ·  Celltrion (4)  ·  Health Institutes of Turkey (4)  ·  University of Cologne (3)  ·  WestVac Biopharma Co., Ltd. (3)  ·  Adaptive Biotechnologies (2)  ·  AstraZeneca (2)  ·  Bayer (2)  ·  Beijing Ditan Hospital (2)  ·  CNBG-Virogin Biotech (Shanghai) Ltd. (2)  ·  Chinese Academy of Medical Sciences (2)

Countries

United States (75)  ·  China (20)  ·  France (18)  ·  Germany (16)  ·  Canada (15)  ·  Spain (15)  ·  South Africa (14)  ·  United Kingdom (14)  ·  Brazil (12)  ·  Turkey (Türkiye) (8)  ·  India (6)  ·  Italy (6)  ·  Japan (6)  ·  Mexico (6)  ·  Argentina (5)

Top investigators

Jason Liggett, PhD (2)  ·  Keith Moore, PHARMD (2)  ·  Mylinh Duong, MD (2)  ·  Stephen Freedman, MD (2)  ·  Yang Wang, Ph.D. (2)  ·  Yunkai Yang (2)  ·  Abdoul Habib Beavogui (1)  ·  Adam Kucharski, MMath, PhD (1)  ·  Ahmet Omma, Assoc. Prof. (1)  ·  Alan Wolfe, MD (1)

Results publications

PMID 34473343, PMID 34551869, PMID 35713300, PMID 37527039, PMID 38400102, PMID 39066372, PMID 39636474, PMID 19647967, PMID 25910392, PMID 27655953, PMID 28501464, PMID 28659436, PMID 31841543, PMID 31924756, PMID 32004427, PMID 32054787, PMID 32190290, PMID 32224310, PMID 32331845, PMID 32374370, PMID 32383624, PMID 32423584, PMID 32495067, PMID 32513308, PMID 32526627, PMID 32692348, PMID 32729446, PMID 32744593, PMID 32785213, PMID 32788708, PMID 32798473, PMID 32859477, PMID 32912793, PMID 32992048, PMID 33050459, PMID 33053279, PMID 33089317, PMID 33110944, PMID 33176080, PMID 33248470, PMID 33259154, PMID 33295781, PMID 33301246, PMID 33329484, PMID 33412596, PMID 33447642, PMID 33452195, PMID 33485468, PMID 33488630, PMID 33495752

NIH funding

2023 (2), 3UH3DK114920-04S2 (1), 3UM1AI068614-14S1 (1), 5U2CDK114886 (1), R01AG085873 (1), U01AI172800 (1), UG1HD078439 (1), UM1AI068614 (1)